Dr. Subbiah on Safety and Efficacy of BLU-667 in RET-Altered Solid Tumors
Vivek Subbiah, MD, associate medical director, Clinical Center for Targeted Therapy, assistant professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy findings of BLU-667 in RET-altered solid tumors in an interview during the 2018 AACR Annual Meeting.
Vivek Subbiah, MD, associate medical director, Clinical Center for Targeted Therapy, assistant professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy findings of BLU-667 in RET-altered solid tumors in an interview during the 2018 AACR Annual Meeting.
According to the findings from the open-label, first-in-human, phase I ARROW trial, the next-generation tyrosine kinase inhibitor BLU-667 appeared to be well tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies.
BLU-667 demonstrated broad antitumor activity with a best overall response rate (ORR) of 37% (95% CI, 20%-56%) in those with RET alterations who received doses ≥60 mg and had at least 1 post-baseline response assessment (n = 30). Patients with non—small cell lung cancers and medullary thyroid cancers had a best ORR of 50% and 40%, respectively.
